ArticleScientific reports2022

Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells.

Amna Mohamed Taha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.